Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients

NCT ID: NCT01765608

Last Updated: 2014-02-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-03-31
• Study Completion Date: 2013-06-30

Brief Summary

This RCT explores the efficacy of Zonisamide (Zonegran®)on overweight/obese in patients with moderate to severe obstructive sleep apnea. Patients will be randomized to receive zonisamide, placebo or nasal continuous positive airway pressure (nCPAP) during 4 weeks. A 5 month open extension part will follow when patients in the tablet groups will all receive zonisamide. Patients in the open CPAP group will continue with CPAP treatment.

Study hypothesis:

Controlled pharmacological weight reduction with Zonisamide will result in elimination of OSA and OSA sequels more effectively than nCPAP due to incomplete compliance with the mechanical treatment and a lack of direct beneficial metabolic effects after nCPAP. Further it is hypothesized that zonisamide has a direct pharmacological effect on respiratory control during sleep by its carbonic anhydrase inhibitory effects and this will result in a reduction of sleep disordered breathing.

Conditions

Sleep Apnea; Obstructive Sleep Apnea; Obesity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Zonisamide

Zonisamide (Zonegran®) 300 mg. Hard white capsule. The total length of zonisamide treatment will be 20 and 24 weeks ± 2 weeks including one or two 4 week titration phases in the placebo and zonisamide groups respectively. Dosing will be down titrated after finished study during 2-3 weeks.The maximum dose after titration will be administrated once daily. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.

Group Type: EXPERIMENTAL

Zonisamide

Intervention Type: DRUG

Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.

Placebo

Matched for Zonisamide. Hard white capsule. Manufactured by Eisai Inc. Placebo tablets will be administered according to a forced stepwise weekly titration scheme with weekly 1 tablet escalations from 1 to 3 tablets daily matching the Zonisamide (Zonegran ®) dosing regimen for a total duration of 4 weeks. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.

Group Type: ACTIVE_COMPARATOR

Placebo

Intervention Type: DRUG

nCPAP

Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S8 or S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed within the first 4 weeks of treatment initiation. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 24 weeks.

Group Type: ACTIVE_COMPARATOR

nCPAP

Intervention Type: DEVICE

Interventions

Zonisamide

Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

nCPAP

Intervention Type: DEVICE

Other Intervention Names

Zonegran®; nCPAP - Nasal Continuous Positive Airway Pressure.; ResMed - S9 AutoSet™; ResMed - S8 AutoSet Spirit™ II

Eligibility Criteria

Inclusion Criteria

• Provision of informed consent prior to any study specific procedures
• Males/females 18 to 75 years
• An Apnea-Hypopnea Index (AHI)>15
• Epworth Sleepiness Scale score (ESS)>6
• Body mass index (BMI) between >27 and <35 kg/m2 (mild to moderate)
• Clinically normal physical findings and laboratory values, as judged by the investigator

Exclusion Criteria

• Hypersensitivity to sulfonamides or zonisamide.
• History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity
• Subjects with a seizure disorder
• Clinically significant renal (serum creatinine >2.0 mg/dL or >130 µmol/L), neurological, metabolic (e.g. Type 1 or 2 diabetes), haematological or hepatic disease (ASAT or ALAT >2 times the upper limit of normal).
• Subjects who have taken any weight loss medications (prescription or over-the-counter) within one month prior to Enrollment
• Subjects with occupations designated as high risk or safety sensitive including patients who have to handle complex machinery or are professional drivers where there may be an increased risk for work or traffic accidents.
• Unstable angina pectoris
• Unstable hypertension (diastolic blood pressure above 100 on treatment for more than 3 months), diabetes (fasting plasma glucose above 7 mmoles/l)
• Uncontrolled congestive heart failure
• Myocardial infarction or coronary vessel intervention within the previous 6 months period
• Subjects with uncontrolled hypertension (defined as a diastolic blood pressure ≥100 mmHg and/or a systolic blood pressure ≥180 mmHg with or without medication). Hypertensive subjects on medications must have been on the same dose of the same antihypertensive medication for at least two months prior to Enrollment.
• Previously diagnosed or treated clinically significant cardiac arrhythmia
• Clinically significant chronic pulmonary or gastrointestinal disease
• Clinical history of depression as judged by the investigator or other previous or present clinically significant psychiatric disease
• Pregnancy or lactation. Women of childbearing potential should use effective birth control prior to and during the study
• Suspected or confirmed poor compliance
• Alcohol or drug abuse during the last year
• Subjects with any other significant condition that, in the opinion of the investigator, could interfere with participation in the study.
• Severe nocturnal hypoxia defined as more than 10 episodes with an oxygen desaturation exceeding 50% or signs of lacking resaturation between desaturations on previous recordings according to investigators judgement.
• Participation in another clinical study during the last 6 months
• Inability to understand and complete the questionnaires

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eisai Inc.

INDUSTRY

Sponsor Role: collaborator

Göteborg University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jan Hedner, MD. Prof.

Role: PRINCIPAL_INVESTIGATOR

Department of Internal Medicine. Center for Sleep and Vigilance Disorders

Locations

Center for Sleep and Vigilance Disorders

Gothenburg, Västra Götaland County, Sweden

Countries

Sweden

Other Identifiers

2009-015859-24

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ZON-01

Identifier Type: -

Identifier Source: org_study_id